Category: Intellectual property
-
Infographic – Microsoft, IBM Lead A.I. Patent Race
The data show as of January 2019, Microsoft leads in the number of A.I. patents in its portfolio with more than 18,300, followed by IBM with about 15,000 patents.
-
Liquid Biopsy Screening Start-Up Launches, Gains $110M
A new enterprise is starting up, developing early-stage cancer screening with a single blood test, based on research at Johns Hopkins University.
-
Companies Partner on Kidney Disease in $2B Deal
A collaboration between biopharmaceutical maker Gilead Sciences and biotechnology company Goldfinch Bio aims to develop precision medicines for treating various kidney diseases.
-
Start-Up to Use Crispr for Heart Disease, Gains $59M
A new biotechnology enterprise plans to apply genetic analysis and the gene-editing technology Crispr to reduce the risk of coronary artery disease.
-
Patent Awarded for Engineered T-Cell Cancer Therapy
An experimental treatment using a person’s modified T-cells from the immune system to attack solid tumor cancers received a U.S. patent.
-
Start-Up Analyzes Images to Determine Medical Condition
A new company provides a service that determines a person’s condition for disease treatments based on indicators derived from an analysis of huge medical-image databases.
-
Biotechs Partner on Gene Silencing in $1.1B Deal
Two biotechnology companies plan to develop new therapies mainly for eye and neurological diseases that silence genes responsible for those conditions.
-
Biotechs Join Forces for Off-the-Shelf Stem Cells
Two biotechnology enterprises working in genome editing and regenerative medicine are sharing their technologies to develop off-the-shelf cell therapies.
-
Start-Up Creating Off-the-Shelf Stem Cell Therapies
A new company is licensing technology from the lab of its co-founder at Harvard University to develop stem cell therapies for any recipients, without causing immune reactions.
-
Crispr Diagnostics Company Launches with $35M Funding
Sherlock Biosciences Inc., a new enterprise offering medical diagnostics based on the genome-editing technology Crispr, is starting up with $35 million in seed financing.